Find your next paid study

VA Eastern Colorado Health Care SystemNCT07194733

~$10 – $1,125

Actual pay is set by the research site.

Inside Liposarcoma Clinical Trials: Patient Experiences Shared While Undergoing Clinical Trials

The study seeks to delve into the firsthand experiences of patients diagnosed with liposarcoma who partake in a separate clinical research featuring a specific…

Liposarcoma

Power Life Sciences Inc.NCT06039046

~$10 – $1,050

Actual pay is set by the research site.

Phase 4

A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms

This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse …

Major Depressive Disorder

Axsome Therapeutics, Inc.NCT06223880

~$25 – $1,400

Actual pay is set by the research site.

Effect of Polygenic Risk Modifiers on Decisions of BRCA1/2 Mutation Carriers at Risk for Prostate Cancer

The purpose of this study is to learn how people with BRCA1/2 mutations respond to genetic risk modifier testing. The researchers will learn more about how peo…

BRCA1/2Geneitic Testing

Memorial Sloan Kettering Cancer CenterNCT07197723

Actual pay is set by the research site.

Continuous Blood Pressure Monitoring During Outpatient Surgery

A before and after interventional cohort study comparing intermittent blood pressure measurement using the oscillometric arm cuff to continuous noninvasive blo…

Blood Pressure

Becton, Dickinson and CompanyNCT07216573

~$10 – $1,125

Actual pay is set by the research site.

Identification of Acute Intermittent Porphyria Modifying Genes

This study proposes to identify the predisposing/protective modifying genes that underlie the acute attacks in symptomatic patients with Acute Intermittent Por…

Acute Intermittent Porphyria (AIP)

Icahn School of Medicine at Mount SinaiNCT05502133

Actual pay is set by the research site.

Phase 1

A Phase 1/1b Study of IAM1363 in Participants With Advanced Cancers Harboring HER2 Alterations

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 i…

HER2 Mutation-Related TumorsHER2HER2-positive Breast Cancer+10 more

Iambic Therapeutics, IncNCT06253871

~$150 – $4,200

Actual pay is set by the research site.

SARS-CoV-2 InfectionInfluenza AInfluenza B+1 more

Usability and Clinical Validation of the CorDx Tyfast Flu A/B/COVID-19 + RSV Multiplex Rapid Test in Anterior Nasal Samples For Over-the-Counter (OTC) Use

This will be a prospective study for the clinical validation of the CorDx Tyfast Flu A/B/COVID-19 + RSV Multiplex Rapid Test for the qualitative detection and …

~$10 – $1,050

Actual pay is set by the research site.

CorDx, Inc.NCT07875270

Phase 1

A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study Evaluating Safety and Pharmacokinetics of VX-272 in Healthy Subjects

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of VX-272 in combination with deu…

Cystic Fibrosis

Vertex Pharmaceuticals IncorporatedNCT07437105

~$500 – $10,500

Actual pay is set by the research site.

Cafe Move: A Novel Program for Prevention of Age-Related Physical Frailty

This project explores a novel means of health promotion and prevention of age-related physical frailty, which is designed to overcome barriers to access and pr…

Aging

University of MontanaNCT05720507

Actual pay is set by the research site.

Point of Care Ultrasound (POCUS)

Point-of-care Ultrasound Utility in the Free Clinic Setting: A Single Site Observational Study of Point of Care Ultrasound Utilization in a Free Clinic of Indianapolis, Indiana

The goal of this observational study is to learn about the clinical utility of point-of-care ultrasound (POCUS) in patients receiving care in a free clinic or …

Indiana UniversityNCT07556341

Actual pay is set by the research site.

Phase 2

A Phase 2 Multicenter, Open-Label, Parallel Cohort Expansion Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-Mesenchymal-epithelial Transition Factor (c-MET) Dysregulation

ABN401-003 is a Phase 2 clinical study to assess efficacy, safety, tolerability and pharmacokinetic profile of ABN401 (vabametkib) in specific populations of a…

Advanced Solid Tumors